ICML 2019 | TRANSCEND CLL04: are the responses to JCAR017 sustained in patients with R/R CLL/SLL?


During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Tanya Siddiqi from City of Hope National Medical Center, Duarte, US, about the TRANSCEND CLL04 trial. Tanya Siddiqi specifically addresses whether the responses to JCAR017 are sustained in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL).

Tanya Siddiqi discusses how over time 5 of 6 patients were in complete remission (CR) after six months, and stayed in CR after nine months, with three patients still in CR after 12 months. She mentions how this therapy could be an excellent option for patients who have relapsed multiple times from different therapies.